Page 1

NGMBIO NGM Bio Provides Business Highlights and Reports Second Quarter 2021 Financial Results August 5 , 2021 • Completed enrollment in 320 - patient Phase 2 CATALINA study of NGM621 , an anti - complement C3 antibody , for the treatment of geographic atrophy ; topline data expected in second half of 2022 • Initiated a Phase 1/2 clinical trial of NGM707 , an ILT2 / ILT4 dual antagonist antibody , in patients with advanced solid tumors • Amended collaboration with Merck to focus primarily on advancing novel medicines for retinal and cardiovascular and metabolic diseases ; NGM gained worldwide rights to its disclosed oncology portfolio as well as additional assets falling outside of the amended collaboration's narrower scope • $ 390.6 million in cash , cash equivalents and marketable securities as of June 30 , 2021 SOUTH SAN FRANCISCO , Calif . , Aug. 05 , 2021 ( GLOBE NEWSWIRE ) -- NGM Biopharmaceuticals , Inc. ( NGM ) ( Nasdaq : NGM ) , a biotechnology company focused on discovering and developing transformative therapeutics for patients , today provided business highlights and reported financial results for the period ending June 30 , 2021 . " With six disclosed pipeline programs , five of which are in the clinic , and additional undisclosed preclinical and research programs , we continue to make meaningful progress towards achieving our mission to translate complex powerful biology with urgency and rigor to deliver life - changing medicines for patients , " said David J. Woodhouse , Ph.D. , Chief Executive Officer at NGM Bio . “ In our sizable oncology portfolio alone , we continue to advance multiple programs that we believe have the potential to benefit patients with a variety of solid tumors . We were pleased to dose our first patient with NGM707 in a Phase 1/2 study this quarter and look forward to presenting interim results from our Phase 1a / 1b dose - finding study of NGM120 at ESMO later this quarter . " " We also continued to make important strides in ophthalmology , with the recent completion of enrollment in our Phase 2 CATALINA study exactly one year after initiation . Our strong balance sheet positions us well to continue progressing our ambitious clinical and research efforts . " Key Second Quarter and Recent Highlights Retinal diseases • Completed enrollment in the Phase 2 CATALINA study of NGM621 in patients with geographic atrophy . NGM completed enrollment in the Phase 2 CATALINA study , a multi - center , randomized , double - masked , sham - controlled clinical trial to evaluate the safety and efficacy of intravitreal , or IVT , injections of NGM621 every four weeks or every eight weeks in 320 patients with geographic atrophy in one or both eyes secondary to age - related macular degeneration . The primary efficacy endpoint is the rate of change in geographic atrophy lesion area , as measured by fundus autofluorescence , or FAF , imaging , over 52 weeks of treatment . NGM anticipates reporting topline data from the CATALINA study in the second half of 2022. Upon completion of a proof - of - concept study in humans , Merck has a one - time option to license NGM621 and its related molecules as well as the additional one - time option to license NGM621 and its related molecules together with all other ophthalmology compounds included within the scope of our ongoing collaboration with Merck . Cancer • Continued enrollment in a Phase 2 placebo - controlled component of the ongoing Phase 1/2 PINNACLES study testing NGM120 as a first - line treatment in combination with gemcitabine and Abraxane® ( paclitaxel protein bound ) in patients with metastatic pancreatic cancer . In March 2021 , NGM initiated a multi - center , randomized , single - blind ( sponsor unblinded ) , placebo - controlled component of NGM120 in combination with gemcitabine and Abraxane as a first line treatment in patients with metastatic pancreatic cancer as part of the ongoing Phase 1/2 trial . This Phase 2 component of the Phase 1/2 study is designed to enroll approximately 60 patients and will assess the efficacy , safety and tolerability of NGM120 or placebo in combination with gemcitabine and Abraxane against both cancer and cancer - related cachexia endpoints . The Phase 1a / 1b dose - finding portion of the study is still ongoing , and NGM expects to report interim results from that portion of the study at the European Society for Medical Oncology in the third quarter of 2021 . • Initiated the Phase 1 portion of a Phase 1/2 Study of NGM707 for the treatment of advanced solid tumors . The Phase 1 portion ( n = 60 ) of the study includes a monotherapy dose escalation arm ( Part 1a ) and a dose - finding arm in combination with KEYTRUDAⓇ ( pembrolizumab ) ( Part 1b ) . The Phase 2 portion ( n = 120 ) of the study will employ a basket design that will include expansion cohorts of patients treated with NGM707 monotherapy ( Part 2a ) or NGM707 in combination with KEYTRUDA ( Part 2b ) .